
    
      RENOVATE Fibrosis will recruit patients with pulmonary fibrosis in acute respiratory failure
      to be randomized to HFNC or NIPPV. Efficacy and safety outcomes measured are dyspnea
      variation, physiological variables (pCO2, respiratory rate, oxygenation), comfort,
      endotraqueal intubation rate, mortality in 28 and 90 days.
    
  